Correlation between insulin-based and C-peptide based homeostatic model assessment of insulin resistance in adults without diabetes in a sub-Saharan African setting: a cross-sectional study.

Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-0500 (Electronic) Linking ISSN: 17560500 NLM ISO Abbreviation: BMC Res Notes Subsets: MEDLINE

Original Publication: London : Biomed Central, 2008.

Diabetes Mellitus, Type 2*/epidemiology ; Insulin Resistance*; Adult ; Blood Glucose ; Body Mass Index ; C-Peptide ; Cameroon ; Cross-Sectional Studies ; Female ; Humans ; Insulin

Objective: To assess the correlation between the insulin-based and C-peptide based HOMA-IR in the general population without diabetes in sub-Saharan Africa as well as to identify factors associated with IR.
Results: This was a cross-sectional study in urban settings in Yaoundé, Cameroon. We included 84 people with a body mass index (BMI) ≥ 18.5 Kg/m² and without diabetes (females: 72.6%; mean age: 37 years). IR was assessed using the following formulae: HOMA-IR INS = fasting insulin (mU/ml) x fasting plasma glucose (FPG) (mmol/L)/ 22.5; HOMA-IR CP1 = fasting C-peptide (mU/ml) x FPG (mmol/L)/ 22.5; and HOMA-IR CP2 = 1.5 + (FPG (mg/dl) x fasting C-peptide (ng/ml))/ 2800. Correlation (rho) between HOMA-IR INS and C-peptide based HOMA-IR was investigated using the Spearman rank test. The median (25th -75th percentiles) HOMA-IR INS , HOMA-IR CP1 , and HOMA-IR CP2 were: 1.94 (1.36-3.50), 0.18 (0.11-0.27) and 9.91 (6.81-14.52), respectively. There was no correlation between the insulin-based and C-peptide-based HOMA-IR indices: rho = 0.043, p = 0.697. IR (HOMA-IR INS ≥ 2.8) was associated with obesity: A BMI ≥ 30 Kg/m² (adjusted odds ratio (aOR): 16.9, 95% confidence intervals (CI): 3.1-92.5) and being a student (aOR: 8.9, 95%CI: 2.1-38.2) were associated with IR.
(© 2022. The Author(s).)

Cardiovasc Diabetol. 2013 Jan 22;12:21. (PMID: 23339473)
J Cell Physiol. 2019 Jun;234(6):8152-8161. (PMID: 30317615)
Eur J Prev Cardiol. 2013 Dec;20(6):1042-50. (PMID: 22952287)
Rev Esp Cardiol. 2005 Dec;58(12):1371-6. (PMID: 16371194)
Open Access Maced J Med Sci. 2015 Jun 15;3(2):315-21. (PMID: 27275243)
Diabetes Care. 2013 Apr;36(4):845-53. (PMID: 23223406)
Semin Nephrol. 2013 Sep;33(5):457-67. (PMID: 24119851)
Psychoneuroendocrinology. 2019 Sep;107:1-8. (PMID: 31055182)
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):62-67. (PMID: 30641777)
Am J Physiol. 1979 Sep;237(3):E214-23. (PMID: 382871)
Lipids Health Dis. 2017 Aug 10;16(1):148. (PMID: 28797289)
Medicina (Kaunas). 2019 May 22;55(5):. (PMID: 31121834)
BMC Endocr Disord. 2014 Aug 09;14:65. (PMID: 25106496)
Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S135-48. (PMID: 11460565)
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004 Aug;29(4):419-23. (PMID: 16134594)
Saudi J Biol Sci. 2018 Dec;25(8):1729-1732. (PMID: 30591792)
J Diabetes Res. 2020 May 20;2020:3781214. (PMID: 32566678)
BMC Med Res Methodol. 2011 Nov 23;11:158. (PMID: 22112229)
BMJ Open. 2020 Sep 14;10(9):e038071. (PMID: 32928857)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)

Keywords: C-peptide; HOMA-IR; Insulin; Insulin resistance; Sub-saharan Africa.

0 (Blood Glucose)
0 (C-Peptide)
0 (Insulin)

Date Created: 20221012 Date Completed: 20221014 Latest Revision: 20221016

20250114

PMC9558417

10.1186/s13104-022-06214-w

36224640